FDA Fast-Tracks Deciphera's Drug for Aggressive Brain Lymphoma

WALTHAM, Mass. – February 17, 2026

In a significant development for patients with a rare and aggressive form of brain cancer, the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for tirabrutinib. Deciphera Pharmaceuticals, part of Japan’s Ono Pharmaceutical Co., Ltd., announced that the agency will review the drug under its accelerated approval pathway for the treatment of relapsed or refractory primary central nervous system lymphoma (R/R PCNSL). The decision sets a target action date of December 18, 2026, under the Prescription Drug User Fee Act (PDUFA), marking a critical milestone for a patient population with desperately few effective therapies.

If approved, tirabrutinib would become the first Bruton tyrosine kinase (BTK) inhibitor commercially available in the United States for this devastating disease. The filing acceptance brings a potential new standard of care into focus for a condition known for its poor prognosis and challenging treatment course.

“R/R PCNSL is a rare and aggressive form of non-Hodgkin lymphoma with particularly poor clinical outcomes,” said Dr. Matthew L. Sherman, Chief Medical Officer of Deciphera, in a statement. “The FDA’s acceptance of tirabrutinib’s NDA for filing is an exciting milestone as it brings us one step closer to our goal of providing patients with R/R PCNSL an important new treatment option.”

A Critical Unmet Need in Brain Cancer

Primary central nervous system lymphoma is an extranodal non-Hodgkin lymphoma that is confined to the brain, spinal cord, eyes, or surrounding membranes. With an annual incidence of just five cases per million people in the U.S., it is a rare diagnosis, but its impact is profound. The disease is notoriously aggressive, with five-year survival rates lingering below 30%.

Initial treatment often involves high-dose chemotherapy, but these regimens can be punishing, and success is not guaranteed. For the 20% to 30% of patients whose cancer is refractory to initial therapy, or the up to 60% who eventually relapse, the path forward becomes alarmingly uncertain. There is no universally accepted standard of care for R/R PCNSL, leaving clinicians and patients to navigate a landscape of limited options, often relying on participation in clinical trials.

Patients frequently endure a difficult diagnostic journey, and symptoms can be severe and varied, ranging from debilitating headaches and seizures to neuropsychiatric changes and cranial neuropathy, depending on the tumor's location. The need for a therapy that is not only effective but also has a manageable safety profile is paramount.

The Promise of a New-Generation Inhibitor

Tirabrutinib is a highly selective, second-generation BTK inhibitor. This class of drugs works by blocking the Bruton tyrosine kinase enzyme, a key component in the B-cell receptor signaling pathway that malignant B-cells rely on to proliferate and survive. By disrupting this signal, BTK inhibitors can trigger the death of cancer cells.

A significant challenge in treating any CNS cancer is the blood-brain barrier, a protective membrane that prevents many drugs from reaching the brain. BTK inhibitors have shown an ability to cross this barrier, making them a promising class of agents for PCNSL. Tirabrutinib appears particularly well-suited for this task, with studies indicating a cerebrospinal fluid-to-plasma concentration ratio of 13-18%, suggesting more robust brain penetration compared to some other BTK inhibitors.

The NDA submission is backed by strong data from the Phase 2 PROSPECT study, which evaluated tirabrutinib as a monotherapy in 48 patients with R/R PCNSL. The results, presented at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, were highly encouraging:

• An overall response rate (ORR) of 67%, meaning two-thirds of patients saw their tumors shrink or disappear.
• A complete response rate (CRR) of 44%, indicating a total disappearance of detectable cancer in nearly half of the patients.
• A median duration of response (DOR) of 9.3 months.

The therapy also demonstrated a manageable safety profile, with the most common treatment-related adverse events being relatively mild and including anemia, rash, and fatigue, with no major cardiac toxicity reported.

Navigating the Accelerated Approval Gauntlet

The FDA's accelerated approval pathway is designed specifically for situations like this—a serious condition with a high unmet medical need where a drug shows promise. It allows the agency to approve a therapy based on a surrogate endpoint, such as tumor shrinkage (response rate), that is considered reasonably likely to predict a real clinical benefit, like longer survival. This enables faster patient access to potentially life-saving medicines.

However, this expedited path comes with a critical requirement: the company must conduct post-marketing studies to confirm the drug's clinical benefit. For tirabrutinib, this confirmatory evidence is expected to come from an ongoing global Phase 3 randomized trial (NCT07104032). This study, which is currently recruiting patients, will compare tirabrutinib against a combination of rituximab and temozolomide, a more established regimen.

The stakes for this confirmatory trial are high. Under the Food and Drug Omnibus Reform Act (FDORA) of 2022, the FDA has strengthened its authority to ensure these post-marketing studies are completed in a timely manner. If the Phase 3 trial fails to verify the clinical benefit seen in the Phase 2 study, the agency can move to withdraw the accelerated approval. This regulatory framework balances the urgent need for new treatments with the scientific rigor required to ensure they are truly safe and effective long-term.

A Strategic Play for Global Expansion

The potential U.S. approval of tirabrutinib represents a cornerstone of the global strategy for Ono Pharmaceutical and its subsidiary, Deciphera. Ono acquired Deciphera in a $2.4 billion deal aimed at bolstering its oncology pipeline and establishing a stronger commercial presence in the U.S. and Europe.

“This is an important milestone on the way to expanding our commercial pipeline and achieving our goal of becoming a global specialty pharma,” stated Toichi Takino, President and COO of Ono Pharmaceutical Co., Ltd.

If it gains approval, tirabrutinib will be the third commercial therapy for the Ono group in the U.S., following the successful launches of QINLOCK® for gastrointestinal stromal tumors and ROMVIMZA® for tenosynovial giant cell tumor. This move would grant the company a significant first-mover advantage in the U.S. market for R/R PCNSL, a niche but valuable space given its orphan drug status.

The drug, known as Velexbru® in other markets, is already approved for R/R PCNSL in Japan, South Korea, and Taiwan, providing a foundation of real-world evidence and regulatory precedent. As Deciphera and Ono prepare for a potential U.S. launch, all eyes in the oncology community will be on the ongoing Phase 3 trial, which will ultimately decide tirabrutinib’s final place in the treatment paradigm for this challenging disease.